medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Metabolic syndrome increases COVID-19-related mortality in the UK Biobank sample

Short title

Metabolic syndrome and COVID-19

Authors

Filip Morys[1], Alain Dagher[1]

[1] Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada

Correspondence

Alain Dagher

Montreal Neurological Institute

3801 University, H3A 2B4 Montreal, Canada

alain.dagher@mcgill.ca

Conflict of interest

The authors have declared that no competing interests exist

Keywords

Metabolic syndrome, obesity, COVID-19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Abstract

Previous studies link obesity and individual components of metabolic syndrome to increased hospitalisations and death rates of patients with COVID-19. Here, in two overlapping samples of over 1,000 individuals from the UK Biobank we investigate whether metabolic syndrome, and its constituent components, increased waist circumference, dyslipidaemia, hypertension, diabetes, and systemic inflammation, are related to increased COVID-19 infection and mortality rates. Using logistic regression and controlling for confounding variables such as socioeconomic status, age, sex or ethnicity, we find that individuals with pre-existing metabolic syndrome (measured on average eleven years prior to 2020) have an increased risk for COVID-19-related death (odds ratio 1.67). We also find that specific factors contributing to increased mortality are serum glucose levels, systolic blood pressure and waist circumference.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Introduction

Since the beginning of the COVID-19 pandemic, mounting evidence supports an association between obesity and poor outcomes (1–3). The association holds for both obesity and for obesity-associated metabolic syndrome, which entails hypertension, diabetes, dyslipidaemia, and systemic inflammation (4). Similarly, obesity and excess adipose tissue have also been associated with higher risk of SARS-CoV-2 infection (5).

Previous studies, however, have tended to use small sample sizes, focus predominantly on the effects of body mass index (BMI) as a measure of obesity, investigate components of metabolic syndrome separately, or not account for confounding factors, such as ethnicity or socioeconomic status (5–8). Since ethnicity and socioeconomic status are themselves associated with obesity and metabolic syndrome (9,10), they could confound interpretation of COVID-19 analyses.

Here, we aim to present a comprehensive evaluation of metabolic risk factors that might be related to poor health outcomes in COVID-19 patients while controlling for confounding variables and limiting potential collider bias, which has previously resulted in incorrect epidemiological conclusions (11,12). We investigate whether metabolic syndrome is related to higher chance for SARS-CoV-2 infection, but also COVID-19-related death.

Materials and Methods

Participants

In this study, we used the UK Biobank dataset – a large scale study with extensive phenotyping carried out in the United Kingdom (13). This study was performed under UK Biobank application ID 35605. COVID-19 test results in the UK Biobank dataset

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

are derived from the Public Health England microbiology database Second Generation Surveillance System that are dynamically linked to the UK Biobank database (14). Here we only included individuals who were recorded as tested for COVID-19. We distinguished between two samples for two aims of our project: Sample 1 – a larger sample (n=12,694) of all individuals who were tested for COVID-19 between 16th March 2020 and 24th August 2020, to investigate risk of COVID-19 infection and how it is related to metabolic syndrome; and Sample 2, a subset of Sample 1 consisting of individuals who tested positive for COVID-19 (n=1,152). We also obtained data on mortality from COVID-19 for all the individuals included in our study population. Among the individuals who tested positive, 180 people (15%) died from COVID-19 infection, allowing us to investigate how metabolic syndrome influences COVID-19-related mortality.

Sample characteristics can be found in Table 1. All participants signed informed consents prior to participating in the UK Biobank study, which was approved by the North-West Multi-centre Research Ethics Committee (11/NW/0382). All UK Biobank actions are overseen by the UK Biobank Ethics Advisory Committee.

Table 1 Participants characteristics.

Measure	Sample 1 Mean (SD) / Percentage (n=12,694)	Sample 2 Mean (SD) / Percentage (n=1,152)
COVID-19 positive patients	9.00%	100%
COVID-19 mortality rate	1.42%	15.63%
Age [years]	70 (8)	68 (9)
Sex distribution	51.84% women	47.14% women
Waist circumference [cm]	92.21 (13.73)	93.50 (13.92)

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Serum HDL [mmol/l]	1.43 (0.38)	1.36 (0.34)
Serum TG [mmol/l]	1.77 (1.02)	1.79 (1.04)
HbA1c [mmol/mol]	35.77 (4.34)	35.93 (4.74)
Serum glucose [mmol/l]	5.00 (0.63)	4.99 (0.65)
Serum C-reactive protein [mg/l]	2.86 (4.58)	3.06 (5.53)
Systolic blood pressure [mmHg]	138.43 (18.55)	137.28 (18.54)
Diastolic blood pressure [mmHg]	82.26 (9.97)	82.49 (10.28)
Diabetes prevalence	8.02%	9.98 %
Hypertension prevalence	42.28%	41.93%

Measures used in the study

To investigate how metabolic syndrome influences COVID-19 infection, hospitalisation, and mortality rates, we used the following measures: waist circumference, serum triglycerides (TG) levels, serum high density lipoprotein (HDL) levels, serum glycated haemoglobin (HbA1c) levels, serum glucose levels, serum C-reactive protein levels (15), previous diabetes diagnosis, resting systolic and diastolic blood pressure (mean values of two measurements), and hypertension diagnosis. In our analyses, we also controlled for age, sex, socioeconomic status (Townsend deprivation index (16), highest achieved educational qualifications, mean family income), smoking status, and ethnic background, physical location of a laboratory where COVID-19 test was performed, and the origin of sample used for COVID-19 test (e.g. nose, throat etc.). For Sample 2, we also used mortality data provided by the UK Biobank – COVID-19-related death was described using the ICD10 identifier U07.1. All COVID-19-unrelated variables were collected on average 11 years prior to COVID-19 tests.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Prior to the analyses, all numeric variables were standardized, all serum level values were log-transformed, and we excluded outliers from the sample (2.2 interquartile range below 1st or above 3rd quartile). If participants were tested for COVID-19 more than once, they were considered positive if at least one test result was positive.

Statistical analyses

The same analyses were performed for each of the two population samples. Data were analysed using R (v. 3.6.0). First, using confirmatory factor analysis in lavaan (v. 0.6-7), we estimated the fit of a latent variable 'metabolic syndrome', which consisted of waist circumference, serum C-reactive protein levels, a latent variable 'dyslipidaemia' (serum HDL and TG levels), and two other latent variables, diabetes and hypertension. The latent variable 'diabetes' consisted of serum glucose and HbA1c levels, as another latent variable, and diabetes diagnosis, while the latent variable 'hypertension' consisted of a blood pressure latent variable (systolic and diastolic blood pressure), and hypertension diagnosis (Figure 1). The model was estimated using robust maximum likelihood estimation and model's fit was evaluated using common indices: comparative fit index (CFI), root mean square error of approximation (RMSEA), and standardized root mean square residual (SRMR). Acceptable fit was confirmed if CFI>0.9, RMSEA<0.1, and SRMR<0.08.

Next, we extracted components of the latent variable 'metabolic syndrome' for each participant and entered them in a logistic regression. The outcome variable in logistic regression for Sample 1 was COVID-19 test result, while for Sample 2, the outcome variable was COVID-19-related death.

In the analyses we used a set of confounding variables to calculate adjusted odds ratio for testing positive for COVID-19: age, sex socioeconomic status, smoking status, and ethnic background.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Finally, for Sample 2 we explored how individual factors contributed to the COVID-19-related mortality by using a logistic regression with individual components of metabolic syndrome, instead of the latent variable 'metabolic syndrome'.

A script for the analysis of the data as well as the output of statistical software can be found at https://github.com/FilipMorys/COVID_MetS .



Figure 1 Confirmatory factor analysis model used to derive the latent variable 'metabolic syndrome'. Squares indicate measured variables; circles indicate latent variables. HbA1c – glycated haemoglobin; HDL – high density lipoprotein; TG – triglycerides; CRP – C-reactive protein.

Results

Metabolic syndrome and the risk of COVID-19 infections

In Sample 1, the confirmatory factor analysis provided an acceptable model fit (CFI=0.934, RMSEA=0.067, SRMR=0.041). In the logistic regression the relation between metabolic syndrome and the chance of having a positive SARS-CoV-2 test

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

did not reach our pre-set statistical significance threshold (p=0.057; odds ratio 1.10; 95% confidence intervals (CI): 0.997-1.214).

Metabolic syndrome is related to an increased COVID-19-related mortality

In Sample 2, the confirmatory factor analysis provided an acceptable model fit (CFI=0.923, RMSEA=0.072, SRMR=0.049). Logistic regression showed that metabolic syndrome is related to an increased mortality rate among COVID-19 positive individuals (p<0.0001) – adjusted odds ratio: 1.67 (95% CI: 1.25-2.23), pointing to a 67% increase for each unit increase on the metabolic syndrome latent variable (Figure 2).

Exploratory analysis with individual components of metabolic syndrome revealed that higher systolic blood pressure, higher serum glucose, and higher waist circumference increased the chance of COVID-19-related mortality – the adjusted odds ratio were 1.30 (95% CI: 1.01-1.68), 1.26 (95% CI: 1.04-1.54), and 1.36 (95% CI: 1.07-1.74), respectively (systolic blood pressure: p=0.044, serum glucose levels: p=0.02, waist circumference: p=0.017; Figure 2).

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure 2 Odds ratio for COVID-19-related death. Dots represent adjusted odds ratios, error bars represent 95% confidence intervals.

Discussion

We investigated whether metabolic syndrome, here defined by increased waist circumference, increased TG levels, decreased HDL levels, systemic inflammation, and the presence of diabetes and hypertension, is a risk factor for COVID-19 infection and mortality. We were able to show that a one unit increase of the latent variable 'metabolic syndrome' results in a 67% higher risk of death because of COVID-19. In contrast, the relation between metabolic syndrome and the likelihood of test positivity was weaker, with an odds ratio of only 1.1 and a confidence interval

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

that included a null effect. In sum, metabolic syndrome contributes little to no risk of test positivity but substantially increases the odds of an adverse outcome.

The results of our study are in line with previous reports linking obesity and individual components of metabolic syndrome with poor COVID-19 outcomes and death (1,3,8,17). Bansal et al. review some of the physiological mechanisms that might mediate the relationship between obesity, related comorbidities and worse outcomes of COVID-19 (18). These include an enhanced expression of the angiotensin I converting enzyme 2 (ACE2), diabetes-related microvascular dysfunction, increased expression of pro-inflammatory cytokines, or activation of the renin-angiotensin-aldosterone system related to hypertension (18). Our results suggest that a number of those mechanisms might at the same time contribute to increased mortality rates related to COVID-19.

Previous studies investigating COVID-19 in the UK Biobank used positive test results obtained between March 16th and April 26th as a proxy of severe COVID-19 (8,19). The rationale for this is that during this time, only patients admitted to hospitals and with COVID-19-like symptoms were tested for COVID-19. Here, we decided to not use this approach for several reasons. First, it is possible that individuals with COVID-19-like symptoms for which they were admitted to a hospital but who did not have COVID-19 were only infected after being admitted. In those cases, positive tests would not reflect COVID-19 severity. Second, it is not possible to determine the exact reason for which inpatients were tested for COVID-19 – positive test results might therefore not only reflect severity of COVID-19 disease, but also testing in anticipation of isolating patients who test positive. For example, patients having to undergo unrelated medical procedures might have undergone precautionary testing.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

We therefore recommend that studies that used this approach as a proxy for COVID-19 severity be interpreted with caution.

For the interpretation of our and similar results from the UK Biobank, it is important to note that the UK Biobank is not a sample representative of the entire UK population and therefore the findings might not be generalizable (20). Furthermore, observational studies such as ours are prone to collider bias, which has already been identified in UK Biobank COVID-19 investigations (21). Collider bias occurs when the sample population is conditioned on a variable that correlates with the variables of interest. For example, during the time period of the current study, it is thought that health workers were more likely to be tested for COVID-19, which may have contributed to incorrect conclusion that cigarette smoking is protective (21). Our study population includes individuals who were seen in a health care setting, who may therefore have a higher incidence of obesity and metabolic syndrome than the general population. However, it is difficult to see how this would account for the effect of obesity on death from COVID-19 among people who tested positive for the virus.

In addition, COVID-19 testing in the UK during the time period of this study was generally restricted to individuals with symptoms such as fever, cough, or loss of smell or taste – asymptomatic COVID-19 individuals were less likely to be tested. This might further increase the extent of collider bias in this and similar studies investigating the predictors of COVID-19 severity or mortality. Current strategies to account for such bias or measure the extent thereof rely on models and strong assumptions that might be incorrect. We therefore suggest that our findings be interpreted with caution. Nonetheless, our model did account for potential collider variables or confounds such as socioeconomic status, ethnicity and age.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

In sum, we used the UK Biobank dataset to confirm that, in individuals who tested positive for COVID-19 in the early stages of the pandemic, metabolic syndrome, and especially visceral adiposity, hypertension, and hyperglycaemia, were associated with an increased risk of death.

Funding

This work was supported by a Foundation Scheme award to AD from the Canadian Institutes of Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

References

1. Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality [Internet]. Vol. 28, Obesity. Blackwell Publishing Inc.; 2020 [cited 2020 Aug 27]. p. 1005. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/oby.22818
2. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19 [Internet]. Vol. 16, Nature Reviews Endocrinology. Nature Research; 2020 [cited 2020 Aug 27]. p. 341–2. Available from: www.nature.com/nrendo
3. Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity Is a Risk Factor for Greater COVID-19 Severity [Internet]. Vol. 43, Diabetes Care. American Diabetes Association Inc.; 2020 [cited 2020 Aug 27]. p. E72–4. Available from: https://doi.org/10.2337/dc20-0682
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation. 2009 Oct;120(16):1640–5.
5. Yates T, Razieh C, Zaccardi F, Davies MJ, Khunti K. Obesity and risk of COVID-19: analysis of UK biobank [Internet]. Primary Care Diabetes. Elsevier Ltd; 2020 [cited 2020 Aug 27]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254007/
6. Townsend MJ, Kyle TK, Stanford FC. Outcomes of COVID-19: disparities in obesity and by ethnicity/race [Internet]. Vol. 44, International Journal of

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Obesity. Springer Nature; 2020 [cited 2020 Aug 27]. p. 1807–9. Available from: https://doi.org/10.1038/s41366-020-0635-2

7. Xie J, Zu Y, Alkhatib A, Pham TT, Gill F, Jang A, et al. Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans. Diabetes Care [Internet]. 2020 Aug 25 [cited 2020 Aug 27];dc201714. Available from: http://care.diabetesjournals.org/lookup/doi/10.2337/dc20-1714

8. Hamer M, Gale CR, Kivimäki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci [Internet]. 2020 Aug 11 [cited 2020 Aug 27];202011086. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.2011086117

9. Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide [Internet]. Vol. 45, Gastroenterology Clinics of North America. W.B. Saunders; 2016 [cited 2020 Aug 27]. p. 571–9. Available from: /pmc/articles/PMC5599163/?report=abstract

10. Pigeyre M, Rousseaux J, Trouiller P, Dumont J, Goumidi L, Bonte D, et al. How obesity relates to socio-economic status: Identification of eating behavior mediators. Int J Obes [Internet]. 2016 Nov 1 [cited 2020 Aug 27];40(11):1794–801. Available from: https://pubmed.ncbi.nlm.nih.gov/27377952/

11. Gaibazzi N, Tuttolomondo D, Guidorossi A, Botti A, Tedeschi A, Martini C, et al. Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19. [Internet]. medRxiv. Cold Spring Harbor Laboratory Press; 2020 Jun [cited 2020 Aug 28]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.05.05.20092015

12. Miyara M, Tubach F, POURCHER V, Morelot-Panzini C, Pernet J, Haroche J,

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

et al. Low rate of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios [Internet]. 2020 May 9 [cited 2020 Aug 28]; Available from: https://doi.org/10.32388/WPP19W.4

13. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med [Internet]. 2015 Mar 31 [cited 2020 Mar 19];12(3):e1001779. Available from: https://dx.plos.org/10.1371/journal.pmed.1001779

14. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, et al. Dynamic linkage of covid-19 test results between public health england's second generation surveillance system and uk biobank. Microb Genomics [Internet]. 2020 Jun 18 [cited 2020 Sep 8];6(7):1–9. Available from: https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000397

15. Elliott P, Peakman TC, UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol [Internet]. 2008 Apr [cited 2020 Mar 19];37(2):234–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18381398

16. Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequality and the North [Internet]. Croom Helm; 1988. Available from: https://books.google.ca/books?id=K9kOAAAAQAAJ

17. Costa FF, Rosário WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS, Barroso WA. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies [Internet]. Vol. 14, Diabetes and Metabolic Syndrome: Clinical Research and Reviews. Elsevier Ltd; 2020

medRxiv preprint doi: https://doi.org/10.1101/2020.10.02.20205716; this version posted October 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

[cited 2020 Aug 27]. p. 809–14. Available from: /pmc/articles/PMC7286828/?report=abstract

18. Bansal R, Gubbi S, Muniyappa R. Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. Endocrinology [Internet]. 2020 Jun 30 [cited 2020 Sep 18];161(10):1–15. Available from: https://academic.oup.com/endo

19. Kuo C-L, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. Journals Gerontol Ser A [Internet]. 2020 May 26 [cited 2020 Sep 29];XX:1–2. Available from: https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glaa131/5843454

20. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants with Those of the General Population. Am J Epidemiol [Internet]. 2017 Nov 1 [cited 2020 Sep 2];186(9):1026–34. Available from: http://creativecommons.

21. Griffith G, Morris TT, Tudball M, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. medRxiv [Internet]. 2020 May 20 [cited 2020 Sep 2];2020.05.04.20090506. Available from: https://www.medrxiv.org/content/10.1101/2020.05.04.20090506v2